UPDATE: Minaris Advanced Therapies has just announced the appointment of Dr. Orla Cloak as the new Chief Executive Officer, effective immediately. This strategic leadership shift comes on July 21, 2025, as the company aims to accelerate its growth in the rapidly evolving field of cell and gene therapies.
Dr. Cloak brings over 20 years of extensive experience in the Pharma and Life Science sectors. She previously held key leadership roles at Lonza for 17 years, including her most recent position as Senior Vice President and Head of the Lonza Bioscience business. Her proven track record in driving innovation and operational excellence positions her as a pivotal leader for Minaris at this critical juncture.
Iain Baird, Chairman of the Board at Minaris Advanced Therapies, expressed enthusiasm about Dr. Cloak’s appointment, stating,
“On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies.”
In her own words, Dr. Cloak remarked,
“I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company’s strong foundations and drive its next phase of growth.”
Minaris Advanced Therapies, headquartered in Philadelphia, Pennsylvania, operates a global contract development and manufacturing organization (CDMO) dedicated exclusively to cell and gene therapies. The company boasts more than 650,000 square feet of infrastructure across the United States, Europe, and Asia. To date, it has successfully manufactured and released over 7,500 GMP batches, supporting therapy developers in early-stage development, clinical trials, and commercial manufacturing.
This announcement signals a new chapter for Minaris Advanced Therapies as it seeks to expand its influence in the biotechnology sector. Investors and industry observers are keenly watching how Dr. Cloak’s expertise will enhance the company’s operational framework and innovation strategy.
As the company embarks on this new era under Dr. Cloak’s leadership, stakeholders and clients can expect focused efforts to foster growth and sustain the momentum of innovation that has defined Minaris.
Stay tuned for further updates as Dr. Cloak assumes her role and outlines her vision for the future of Minaris Advanced Therapies.
